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BY-NC-ND license (http://creativecomBackground/Purpose: The aims of the current study were to determine whether patients with
conduct disorder (CD) showed an abnormal availability of serotonin reuptake transporter
(SERT), and if their hyperkinetic symptoms, impulsivity, and quality of life were correlated
with the availability of SERT.
Methods: We recruited 14 drug-naı¨ve patients with CD and eight age-matched healthy controls
(HCs). The adult attention-deficit/hyperactivity disorder (ADHD) self-report scale (ASRS), Bar-
rett impulsivity scale (BIS), and the World Health Organization quality of life-brief version
(WHOQOL-BREF) scale were administered. Positron emission tomography (PET) of the brain
with 4-[18F]-ADAM was arranged for SERT imaging.
Results: SERT availability was significantly reduced in the striatum and midbrain of patients
with CD. Quality of life and inattention symptoms were also significantly correlated with the
availability of SERT in the prefrontal cortex.
Conclusion: The study suggested that a reduction in the availability of SERT might be associ-
ated with CD and could potentially predict poor quality of life or symptoms of inattentionave no conflicts of interest relevant to this article.
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Conduct disorder (CD) and oppositional defiant disorder
are the disorders most frequently comorbid with
attention-deficit/hyperactivity disorder (ADHD).1 CD is
a relatively more severe behavioral problem, and occurs
in 20% of patients with ADHD and can alter the course and
prognosis of ADHD.2 It also accounts for the greatest cost
in terms of psychological, psychiatric, and social
services.3 CD may be associated with an increase in the
severity of symptoms of both learning and disruptive
behavior disorders,4 which may affect patients’ educa-
tional outcomes. Likewise, CD has been identified as the
most relevant risk factor predisposing to substance
use disorders in adulthood.5 The presence of CD in
adolescents doubles their risk of substance use,6 and also
influences the risk of other psychiatric comorbidities, such
as higher baseline rates of major depression, bipolar
disorder, and multiple anxiety disorders.7 Finally, CD
also negatively affects self-reported health-related qual-
ity of life among children and adolescents, with less
warmth and closeness and more conflict in familial re-
lationships.8,9 These children may inflict serious physical
and psychological harm on others, and are also at
increased risk for self-injury and death by homicide or
suicide.10,11
Comorbid CD also complicates treatment for ADHD, and
may diminish the effectiveness of some medications12;
the effect of disruptive behavior disorders on adherence
to prescribed medication regimens may also occur.13 Cli-
nicians should therefore attempt to identify the presence
of CD as early as possible, and provide potentially effec-
tive behavioral and pharmacologic interventions.
It has been reported that lower serotonergic responsivity
in hyperkinetic children may predict the development of
conduct and antisocial personality disorders.14 It has also
been suggested that impulsive aggressive symptoms are
associated with reduced serotonin uptake, increased syn-
aptic levels of serotonin, and reduced postsynaptic recep-
tor responsiveness.15 Previous studies using positron
emission tomography (PET) found that abnormal levels of
serotonin in the brain were associated with aggressive/
impulsive behaviors.16 Other studies found that the avail-
ability of serotonin reuptake transporter (SERT) was not
significantly different between hyperkinetic patients and
healthy controls (HCs),17 but there have been inconsistent
findings that showed increased rather than decreased se-
rotonin, as measured by CSF 5-HIAA, a metabolite of sero-
tonin, was associated with aggression in children.18
Moreover, there are limited disorder-specific biomarkers
for symptoms including poor impulse control, aggression,
and emotional dysregulation. We hypothesized thatChang C, et al., Abnormal seroto
edical Association (2016), http://serotonergic dysfunction plays a role in the vulnerability of
patients with CD. We measured SERT availability in male CD
patients with PET using 4-[18F]-ADAM as a tracer. The aims
of this study were to investigate abnormalities in the
availability of SERT in the brain, and to determine potential
correlations of this abnormality with symptom severity and
quality of life.
Methods
Participants
Fourteen adult males (mean age, 26.71 4.32 years) whose
symptoms met the DSM-IV TR criteria for conduct disorder
were recruited into our study from the outpatients at the
Tri-service General Hospital in Taipei, Taiwan. The patients
were assessed by trained clinicians using the Kiddie
Schedule for Affective Disorders and Schizophrenia-
Epidemiology version (K-SADS-E). All of the patients with
CD had both childhood and current symptoms of ADHD. The
control group (mean age, 29.38 2.83 years) was made up
of eight healthy men whose comparable scans were avail-
able in the PET Centre of the Tri-service General Hospital.
All patients were first-time visitors at our psychiatric clinic
and their medication status was evaluated by direct report
and chart review. The experimental protocol was approved
by the Institutional Review Board for the Protection of
Human Subjects at the Tri-Service General Hospital, Na-
tional Defense Medical Center in Taipei, Taiwan. All par-
ticipants gave written informed consent.
Exclusion criteria, including ongoing psychiatric or so-
matic comorbidity or other neurodevelopmental disorders,
were assessed using the mini-international neuropsychiatric
interview of the DSM-IV. We did not specifically exclude
patients with substance exposure because comorbidity with
substance use is prevalent in this group of patients.
The CD patients were evaluated using the adult ADHD
self-report scale (ASRS), the Barrett impulsivity scale (BIS),
and the World Health Organization Quality of Life-brief
version scale (WHOQOL-BREF). All patients in the CD group
were drug naı¨ve in that they had never been treated with
mood stabilizers, antidepressants or methylphenidate, or
other psychotropic agents.
Radiopharmaceutical and PET procedure
The 4-[18F]-ADAM was synthesized in an automated syn-
thesizer.19 All the 4-[18F]-ADAM formulations used in this
study were prepared in our PET cGMP laboratory, which is
inspected regularly by the Council of Atomic Energy and the
Department of Health, Taiwan.nin transporter availability in the brains of adults with conduct
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Table 1 Demographic data and scores on rating scales of
the participants.a
CD patients (nZ 14) HCs (nZ 8) p*
Age (y) 26.71 4.32 29.38 2.83 0.19
BISb 67.36 9.20 d d
ASRSb 28.82 7.65 d d
WHOQOL-BREFb 88.64 15.23 d d
Data are shown as mean SD.
ASRSZ adult attention-deficit/hyperactivity disorder self-
report scale; BISZ Barrett impulsivity scale; CDZ conduct
disorder; HCsZ healthy controls; SDZ standard deviation;
WHOQOL-BREFZWorld Health Organization quality of life-brief
version.
* p< 0.05 denotes statistical significance.
a Comparisons were made among groups.
b Only CD patients were evaluated with these scales.
Table 2 Comparison of mean SERT BPND in four ROIs in
patients with CD.a
CD patients (nZ 14) HCs (nZ 8) Z p*
PFC 0.310 0.118 0.285 0.118 0.819 0.413
ST 0.625 0.139 0.834 0.249 2.116 0.034*
TH 0.850 0.224 0.949 0.210 1.024 0.306
MB 1.00 0.199 1.198 0.119 2.184 0.029*
Data are shown as mean SD.
* p< 0.05 denotes statistical significance.
BPNDZ binding potential of nondisplaceable radioligand in
brain tissue; CDZ conduct disorder; HCZ healthy control;
MBZmidbrain; PFCZ prefrontal cortex; ROIsZ regions-of-in-
terest; STZ striatum; SERTZ serotonin reuptake transporter;
THZ thalamus; ZZ z value of the ManneWhitney U test.
a Comparisons were made among groups.
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placed on the scanner’s motorized adjustable bed with
their head immobilized with a padded Velcro strap and
aligned with the assistance of laser crosshairs. All partici-
pants underwent a low-dose computerized tomography
(CT) scan (130 kVp, 50 mAs, 0.8 s tube rotation, 4 mm slice
collimation, and a pitch of 3). They then underwent a static
PET scan in three-dimensional mode using a BIOGRAPH PET/
CT scanner (Biograph Duo; Siemens, PA, USA). Total PET
imaging was begun at 120 minutes after intravenous bolus
injection of 7.94 1.13 mCi 4-[18F]-ADAM, and the scanning
required a total of 20 minutes. This scanner had a trans-
verse field-of-view of 58.5 cm, an axial field-of-view of
15.5 cm, and a spatial resolution of 4.8 mm. PET images
were reconstructed in a 512 512 64 matrix with a pixel
size of 0.519 mm 0.519 mm 2.4 mm using the ordered
subset expectation maximization method (six iterations and
16 subsets) with a 3 mm full-width half maximum Gaussian
filter.
PET image acquisition
Images were analyzed using PMOD software for Windows
(version 3.0; PMOD group, Zurich, Switzerland). Each pa-
tient’s PET image was automatically coregistered with the
corresponding CT scan and then manually adjusted by an
experienced physician. The CT was loaded to provide an
anatomical reference, and regions-of-interest (ROIs) were
defined on reconstructed and summated PET images. ROIs
were drawn over the midbrain, striatum, thalamus, and
prefrontal cortex, where the loci of serotonergic cell bodies
and their main projections are located. We used the cere-
bellum as a background reference because of its low SERT
concentration when compared to other brain regions.20 To
reduce the confounding effects of SERT binding in the
cerebellum, the white matter and vermis were excluded,
and only the posterior half of the cerebellar cortex was
delineated. The binding potential (BP) of 4-[18F]-ADAM was
quantified using a previously described ratio method
comparing specifically bound radioligand to non-
displaceable radioligand in brain tissue (BPND) at equilib-
rium.21 As the uptake of 4-[18F]-ADAM has been reported to
reach equilibrium approximately 120e140 minutes after its
injection in human patients,21 we applied a 120 minute
delay to the frames for the equilibrium ratio method in our
modeling. The BPND of 4-[
18F]-ADAM in the target region was
calculated by subtracting the tissue radioligand activity in
the nondisplaceable region (CCB) from the tissue radio-
ligand activity in the target region (CROI), and then dividing
the result by the tissue radioligand activity in the non-
displaceable region. The equation was defined as follows22:
BPND Z BP’ Z (CROI  CCB)/CCB. (1)
We measured the SERT BPND to represent the SERT
availability and the investigator analyzing the images was
blind to all participant information.
Statistical analysis
Age, scores on the rating scales, and SERT BPND of the pa-
tients were presented as means SD. An unpaired t test wasPlease cite this article in press as: Chang C, et al., Abnormal seroto
disorder, Journal of the Formosan Medical Association (2016), http://used for comparison of continuous variables in the de-
mographic data. To compare availability of SERT, a Man-
neWhitney U test was performed. Spearman’s correlation
was used to test the association of SERT availability in
different brain regions with the scores on the rating scales.
Statistical analysis was performed using SPSS software
(version 20.0, IBM, Chicago, IL, USA) on a personal computer.
A p value< 0.05 was considered statistically significant.Results
The demographic data of the patients with CD and the HCs,
and the findings from the K-SADS-E, ASRS, and WHOQOL-
BREF scales are shown in Table 1. The mean age of the CD
group was 26.71 4.32 years, and that of the HCs was
29.38 2.83 years. The ages were not significantly
different between groups (pZ 0.188).
In the CD group, the mean ASRS score was 28.82 7.65,
in the range of the 80th percentile to the 95th percentile for
the general population. The mean BIS score was
67.36 9.20, and the mean WHOQOL-BREF score was
88.64 15.23.
All 14 patients with CD and the eight HCs completed their
PET scans. The values of SERT BPND in the midbrain,nin transporter availability in the brains of adults with conduct
dx.doi.org/10.1016/j.jfma.2016.07.012
Figure 1 A representative PET/CT fused image demonstrating the ROI delineation and regional uptake of 4-[18F]-ADAM at
120e140 minutes after radioligand injection. (A) CD patients; (B) healthy controls; (C) red indicates the highest uptake, blue
indicates the lowest uptake of the radiotracer. Note the high uptake of 4-[18F]-ADAM in SERT-rich regions including the midbrain,
thalamus, and striatum, and low uptake in the PFC. CTZ computerized tomography; PETZ positron emission tomography;
PFCZ prefrontal cortex; ROIZ regions-of-interest; SERTZ serotonin reuptake transporter.
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2. SERT levels were significantly lower in the midbrain
(0.998 0.199 vs. 1.198 0.119; zZ2.184, pZ 0.029),
and striatum (0.624 0.139 vs. 0.834 0.249; zZ2.116,
pZ 0.034) of the CD patients. No statistically significant
differences were detected in the prefrontal cortex
(0.310 0.118 vs. 0.285 0.118; zZ0.819, pZ 0.413) or
thalamus (0.850 0.224 vs. 0.949 0.210; zZ1.024,
pZ 0.306). Representative PET/CT fused images of the
distribution of 4-[18F]-ADAM are shown in Figure 1.
In patients with CD, there was a significant negative
correlation between the availability of SERT in the pre-
frontal cortex and the WHOQOL-BREF score (rhoZ0.670,
pZ 0.024). A positive correlation between the availability
of SERT in the prefrontal cortex and the ASRS inattention
subscore was also found (rhoZ 0.603, pZ 0.022)
(Figure 2); however, these correlations were not found in
the other brain regions (Table 3).
There was no significant correlation between the avail-
ability of SERT in any of the four brain regions and the ASRS
total scores: prefrontal cortex (rhoZ 0.364, pZ 0.201),
striatum (rhoZ 0.175, pZ 0.549), thalamus
(rhoZ0.173, pZ 0.534), and midbrain (rhoZ0.286,
pZ 0.321). No correlations between the availability of
SERT and the ASRS hyperactivity subscore or BIS scores in
patients with CD were found (Table 3).Please cite this article in press as: Chang C, et al., Abnormal seroto
disorder, Journal of the Formosan Medical Association (2016), http://Discussion
We found that decreased availability of SERT in the stria-
tum and midbrain was associated with CD. Furthermore,
there was a significant positive correlation between the
availability of SERT in the prefrontal cortex and the ASRS
inattention subscore. To the best of our knowledge, this
was the first study to investigate the availability of SERT in
the brain with PET in adult males with CD, although a
previous PET study using [11C] MADAM as a tracer in adult
females with ADHD did not find an abnormal availability of
SERT in patients with ADHD, which is often a predisposition
to CD.17
Disruptive brain functional connectivity23 and reduced
cortical tissue24 were found in patients with CD and might
be related to the dysfunction in regulating reactive
aggression.25 Moreover, patients with CD often had
impaired executive function,26 associated with lower
brain SERT binding and deficient serotonin.27,28 The
reduced binding of H3-labeled imipramine to serotonin
uptake sites in the platelets of CD children has been
reported,29 as has the observation that hyperkinetic
patients have a 25% reduction in platelet SERT binding
capacity.30 Our findings appear to support the hypothesis
that serotonin dysfunction might be involved in the
pathobiology of CD. It is unclear if the abnormalnin transporter availability in the brains of adults with conduct
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Figure 2 The correlation of scores on the ASRS-I. (A) ASRS-I;
(B) WHOQoL-BREF, with SERT BPND in the PFC2. ASRSZ adult
attention-deficit/hyperactivity disorder self-report scale;
ASRSIZ ASRS inattention subscore; BPNDZ binding potential of
nondisplaceable radioligand in brain tissue; PFC2Z prefrontal
cortex; SERTZ serotonin reuptake transporter; WHOQoL-
BREFZWorld Health Organization quality of life-brief version.
Table 3 Correlation of SERT BPND in four ROIs in CD patients.
a
PFC ST
rho p rho
ASRS 0.340 0.306 0.124
ASRS-I 0.636 0.035* 0.384
ASRS-H 0.247 0.465 0.032
BIS 0.155 0.650 0.291
WHOQoL-BREF 0.670 0.024* 0.360
* p< 0.05 denotes statistical significance.
ASRSZ adult attention-deficit/hyperactivity disorder self-report sca
tivity subscore; BISZ Barrett impulsivity scale; BPNDZ binding poten
disorder; MBZmidbrain; PFCZ prefrontal cortex; rhoZ Spearman’s
interest; STZ striatum; SERTZ serotonin reuptake transporter; THZ
life-brief version.
a Correlations were made among SERT BPND in four ROIs and scores
SERT availability in conduct disorder 5
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Please cite this article in press as: Chang C, et al., Abnormal seroto
disorder, Journal of the Formosan Medical Association (2016), http://availability of serotonin transporter binding in the brain is
a primary phenomenon that reduces the clearance of
intrasynaptic serotonin through SERT, and thus increases
intrasynaptic serotonin, or a compensatory manifestation
that downregulates SERT in response to decreased
intrasynaptic serotonin. Our findings suggest that
abnormal brain serotonin transmission might be associ-
ated with CD.
CD is considered a distinct pathological entity in which
more severe aggression and impulsivity are present than
they are in ADHD alone.31 Given the influence of aggression
in determining the appropriate psychopharmacological
treatment, a better understanding of the characteristics of
aggression is important. Referring to previous brain PET
studies of the availability of SERT in relation to aggression,
one study used [11C]McN5652 as a tracer and found signifi-
cant SERT reductions in the anterior cingulate and more
modest reductions (8e29%) in all other regions, including
the midbrain. These reductions were associated with
impulsive aggression in patients with both intermittent
explosive disorder and comorbid mood disorders as well as
personality disorders.32 However, in another PET study,33
[11C]-DASB was used as a tracer to examine 14 healthy
males with impulsive aggression but without callous un-
emotional traits. These authors reported that the avail-
ability of SERT was significantly increased in the midbrain,
but was lower in cortical regions. The inconsistencies be-
tween our findings and these studies may reflect the small
sizes of their study groups, differences in methodology, and
the different individuals they recruited, all of which may
have contributed to limitations in the results. Our findings
do provide further evidence that the abnormal availability
of SERT is possibly associated with CD and is characterized
by impulsiveness and aggression.
Our findings revealed that the abnormal availability of
SERT in the brains of young adults with CD was itself a
predictor of poor outcomes, such as violent behavior,
suicide, substance use disorders, and mood disorders in
the future.7 This suggests that CD is a distinct pathological
entity with impaired functions.1 In addition, our studyAvailability
TH MB
p Rho p rho p
0.716 0.253 0.453 0.395 0.229
0.243 0.252 0.455 0.201 0.553
0.926 0.279 0.407 0.420 0.198
0.385 0.136 0.689 0.009 0.979
0.277 0.050 0.884 0.333 0.318
le; ASRS-IZ ASRS inattention subscore; ASRS-HZ ASRS hyperac-
tial of nondisplaceable radioligand in brain tissue; CDZ conduct
rank correlation coefficient or Spearman’s rho; ROIsZ regions-of-
thalamus WHOQOL-BREFZWorld Health Organization quality of
of scales.
nin transporter availability in the brains of adults with conduct
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was negatively associated with subjective quality of life in
patients with CD. A single-photon emission computed
tomography (SPECT) study has also found that serotonin
availability in the midbrain was positively correlated with
quality of life in healthy males, and that supposed central
serotoninergic activity may play a role in overall quality of
life ratings.34 To the best of our knowledge, our study was
the first to report the association of the availability of
SERT in the prefrontal cortex and quality of life in CD
patients. It suggests that impaired executive function and
emotional regulation might then account for that poor
quality of life.
Several methodological considerations relevant to our
study should be noted. First, we chose 4-[18F]-ADAM as a
tracer because it has high specific binding for a
reasonably long time for imaging brain SERT in
humans.21 18F has some further advantages over 11C,
such as greater spatial resolution, a long half-life which
enables the optimization of the scanning protocol, and
convenience in radiosynthesis. Second, patients in this
study were drug naı¨ve, without any experience of
medication or any other psychotropic drug. Our study
did have several limitations. First, we used self-reported
measures that depended on the patient’s honesty and
capacity for self-reflection; however, previous reports
have noted that the consistency of self-reported mea-
surement was consistent with the results of final diag-
nosis.35 In addition to this, the HCs did not report
severe impulsivity and we supposed their impulsivity
was within the normal range. Second, although the pa-
tients went through comprehensive diagnostic assess-
ments, they were currently not medicated, but these
results may be limited by the fact that some of the
patients we recruited had substance-use disorders that
might have influenced the availability of SERT.36,37
Substance use is almost inevitable in young adults with
CD.38 Finally, our small sample size was also a limita-
tion, and further research with larger samples with
phenotypic impulsive aggression is necessary. We
selected specific brain regions as the targets to compare
the availability of SERT between two groups in the PET
exams; however, correction for the results of multiple
comparisons is needed to validate our preliminary find-
ings. Furthermore, the results of our study cannot be
generalized to individuals with either ADHD alone or CD
alone since we recruited only young adults with CD and
hyperkinetic symptoms. The implication of our results
was also limited by the effects of gender39 intelli-
gence,40 or quality of life34 in HCs on the availability of
SERT in the brain, as we only recruited male patients
and did not measure the intelligence or quality of life
among HCs.
It is important to identify CD among children and ado-
lescents. Our study provided new insights into the avail-
ability of SERT in individuals with CD and hyperkinetic
symptoms. Reduction in the availability of SERT in the
striatum andmidbrain in patients with CDmight suggest that
abnormal serotonin transmission is involved in the pathobi-
ology of CD. This study provided evidence that future
treatment should target the serotonin system, although
more systematic studies will be needed to confirm this.Please cite this article in press as: Chang C, et al., Abnormal seroto
disorder, Journal of the Formosan Medical Association (2016), http://References
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